A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase of Trial: Phase III
Latest Information Update: 30 May 2018
At a glance
- Drugs Ravulizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 08 Feb 2018 According to an Alexion media release, enrollment and dosing is ongoing.
- 06 Sep 2017 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.
- 06 Sep 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.